



This updated was published on www.baxter.com on 2024-10-9. For more up-to-date information, please go to [Hurricane Helene Updates | Baxter](#).

Baxter's North Cove manufacturing site was significantly impacted by the rain and storm surge from Hurricane Helene, which was unprecedented in Western North Carolina and resulted in water flooding the facility.

Supporting our employees in the impacted communities, bringing the North Cove facility back online and helping to ensure ongoing supply to patients are our top priorities.

Below is an update on supply continuity:

Allocations: As previously shared, Baxter is advancing multiple paths to help ensure we are appropriately managing inventory and minimizing disruption to patient care as we work to fully restore our North Cove manufacturing operations. This includes implementing allocations, which limit what a customer can order based on historical purchases and medical necessity as well as available and projected inventory. Allocations help limit stockpiling and increase the likelihood of equitable access to available products.

Based on Baxter's efforts to increase manufacturing capacity at its other sites and our current assessment of anticipated timing of inbound products and air shipments, **we are increasing the current U.S. allocation levels of our highest demand IV fluids for direct customers from 40% to 60%, and for distributors from 10% to 60%, effective Wednesday, Oct. 9.** We are also increasing high concentration dextrose and sterile water for injection allocations and expect to be in a position to make additional increases for certain product codes by early November. Due to the vulnerable patient population they serve, allocations for IV solutions and nutrition products for designated children's hospitals were increased to 100%.

We continue to actively deliver supplies to current peritoneal dialysis (PD) patients. The allocations for PD solutions remain as communicated, and we are working with our partners to conserve and identify alternate sources of supply across all PD product categories. In addition, we are closely monitoring stock levels and working with partners and professional bodies to optimize utilization of PD supplies.

Our goal continues to be to restore customers to 100% allocation levels as soon as possible. This would be achieved through a combination of importing product from other Baxter facilities and the resumption of operations and scale up of production at our North Cove facility.

Site Status: As shared in our Oct. 7 update, Baxter continues to scale production across its global locations and is working closely with FDA on temporary importation of products to increase available inventory. Based on 1) the current status of our remediation efforts, 2) our expectations regarding our ability to reallocate capacity from other Baxter facilities, and 3) initiation of temporary importation on certain products, **our goal is to restart North Cove production in phases and return to 90% to 100% allocation of certain IV solution product codes by the end of 2024.**

As our CEO, Joe Almeida, reiterated, "We will spare no resource — human or financial — to restart operations and help ensure patients and providers have the products they need."

We are aware that there is a tremendous amount of misinformation circulating in the marketplace, and we are disheartened to see blatant speculation fueling patient and customer concerns. As always,



prioritizing patient care is our goal, and it is our sincere hope that everyone works to uphold this standard.

We are appreciative of and grateful for the ongoing support and patience of our customers and partners as we work diligently to fulfill our Mission to Save and Sustain Lives for our employees, patients and communities.

Resources for Customers

- [October 1 Medical Information Letter for Home Dialysis Customers](#)
- [September 30 Medical Information Letter for Healthcare Facilities](#)
- [September 29 Initial Notification Letter](#)